<?xml version="1.0" encoding="iso-8859-1" standalone="no" ?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>PRO000000000000510010</messagenumb>
    <messagesenderidentifier>EMDSERONO</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125162937</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">2</safetyreportversion>
    <safetyreportid lang="en">BR-US-EMD Serono, Inc.-7130233</safetyreportid>
    <primarysourcecountry>BR</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20130125</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20120502</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20130116</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">BR-Merck KGaA-7130233</companynumb>
    <medicallyconfirm>2</medicallyconfirm>
    <primarysource>
      <reporterfamilyname>Unknown</reporterfamilyname>
      <reportercountry>BR</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <senderorganization>US-EMD Serono, Inc.</senderorganization>
      <senderdepartment>US Product Surveillance and Quality Assurance</senderdepartment>
      <sendertitle>Dr</sendertitle>
      <sendergivename>Daryl</sendergivename>
      <senderfamilyname>Dawson</senderfamilyname>
      <senderstreetaddress>One Technology Place</senderstreetaddress>
      <sendercity>Rockland</sendercity>
      <senderstate>MA</senderstate>
      <senderpostcode>02370</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>781-681</sendertel>
      <sendertelextension>2564</sendertelextension>
      <sendertelcountrycode>+1</sendertelcountrycode>
      <senderfax>781-681</senderfax>
      <senderfaxextension>2961</senderfaxextension>
      <senderfaxcountrycode>+1</senderfaxcountrycode>
      <senderemailaddress>usps@emdserono.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>US-A-Food and Drug Administration</receiverorganization>
      <receiverdepartment>AERS</receiverdepartment>
      <receivertitle>Mr</receivertitle>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>CDER</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
      <receivercity>Rockville</receivercity>
      <receiverstate>MD</receiverstate>
      <receiverpostcode>20851</receiverpostcode>
      <receivercountrycode>US</receivercountrycode>
      <receivertel>3017709299</receivertel>
      <receivertelcountrycode>001</receivertelcountrycode>
      <receiverfax>3017706614</receiverfax>
      <receiverfaxcountrycode>001</receiverfaxcountrycode>
      <receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
    </receiver>
    <patient lang="en">
      <patientinitial>AAR</patientinitial>
      <patientbirthdateformat>102</patientbirthdateformat>
      <patientbirthdate>19421228</patientbirthdate>
      <patientsex>2</patientsex>
      <reaction>
        <primarysourcereaction lang="en">NODULE ON RIGHT BREAST (UNDERGONE A SURGERY TO REMOVE THE WHOLE RIGHT BREAST)</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10006293</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10006272</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">EMOTIONALLY SUFFERING</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10014551</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10014551</reactionmeddrapt>
        <termhighlighted>2</termhighlighted>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">PAIN ON THE INJECTION SITE</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10022086</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10022086</reactionmeddrapt>
        <termhighlighted>2</termhighlighted>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REBIF</medicinalproduct>
        <drugbatchnumb>AU002057</drugbatchnumb>
        <drugauthorizationnumb>103780</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugstructuredosagenumb>44</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugseparatedosagenumb>3</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10063399</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20090424</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20121205</drugenddate>
        <drugtreatmentduration>4</drugtreatmentduration>
        <drugtreatmentdurationunit>801</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <activesubstance>
          <activesubstancename>INTERFERON BETA-1A</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10006272</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10006272</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10014551</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10014551</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022086</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022086</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Famotidine</medicinalproduct>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Deflazacort</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Hydrochlorothiazide</medicinalproduct>
        <drugstructuredosagenumb>6.25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Paroxetin</medicinalproduct>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Nortriptiline (nortriptyline)</medicinalproduct>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Cyclobenzaprine</medicinalproduct>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Acetaminophen</medicinalproduct>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Metformin</medicinalproduct>
        <drugstructuredosagenumb>500</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Zolpidem</medicinalproduct>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical lang="en">This solicited case report from a patient in Brazil was initially received at Merck Serono on 02 May 2012. 
A 69-year-old (estimated age at the time of reporting) female patient experienced nodule on right breast (undergone a surgery to remove the whole right breast), emotionally suffering and pain on the injection site while being treated with Rebif.
The event nodule on right breast (undergone a surgery to remove the whole right breast) was considered as medically significant by the company.
The patient's relevant medical history was not reported.
The patient's concomitant medications included famotidine 40 mg, deflazacort 5 mg, hydrochlorothiazide 6.25 mg, paroxetin (paroxetine) 20 mg, nortriptiline (nortriptyline) 10 mg, cyclobenzaprine 2.5, acetaminophen 150 mg, metformin 500 mg and zolpidem at an unknown dose. No further information was provided.
The patient received Rebif (interferon beta 1a) at a dose of 44 mcg three times a week from 24 Apr 2009 for relapsing remitting multiple sclerosis. 
On an unspecified date, the patient presented with nodule on right breast. A surgery was scheduled after cardiologist evaluation. The patient also experienced pain on the injection site because her skin was drier. On 12 Dec 2012, the patient underwent a surgery in order to remove the whole right breast. On 05 Dec 2012, Rebif therapy was discontinued following the physician's advice, while the patient had been receiving chemotherapy sessions. The patient was emotionally suffering and did not want to talk about it. The physician was aware about the events, but follow up contacts were not allowed.
At the time of reporting, outcome of the events nodule on right breast (undergone a surgery to remove the whole right breast) and emotionally suffering was not reported and the event pain on the injection site was not resolved. 

** Follow up information was received from the patient on 16 Jan 2013. It included the following: event nodule on right breast updated to nodule on right breast (undergone a surgery to remove the whole right breast), new non serious event (emotionally suffering) and Rebif therapy details (Rebif stop date).

** Follow up version was created upon clarification received from the Local Merck affiliate on 24 Jan 2013. It included the following:  Patient's initials changed (AAR).</narrativeincludeclinical>
        <sendercomment lang="en">Nodule on right breast (undergone a surgery to remove the whole right breast) [Breast mass] in a 69-year-old (estimated age at the time of reporting) female patient, an unspecified period of time after the first administration of Rebif (interferon beta 1a) for the treatment of relapsing-remitting multiple sclerosis. In addition, the patient experienced the following non serious events: emotionally suffering [Emotional disorder] and pain on the injection site [Injection site pain].
Temporal relationship: potentially compatible. Latency: not assessable (events onset dates not reported).
Dechallenge: not applicable for nodule on right breast  (treatment given), unknown for emotionally suffering (outcome after change not reported) and negative for pain on the injection site.
Alternative explanations: the role of genetic and environmental factors cannot be ruled out. Concomitant treatment with deflazacort, paroxetine, nortriptyline, zolpidem and cyclobenzaprine and concurrent breast nodule could have contributed to the occurrence of emotional disorder.
Evaluation by reporter (patient): not reported.
Evaluation by company: In absence of sufficient information to fully assess the case, nodule on right breast (undergone a surgery to remove the whole right breast) and emotionally suffering have been assessed as causally related to Rebif. Injection site pain is assessed as related to Rebif.
Breast mass and Emotional disorder are unlisted and Injection site pain is listed for Rebif as per reference safety information.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr>
